Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ZIOPHARM |
---|---|
Information provided by: | ZIOPHARM |
ClinicalTrials.gov Identifier: | NCT00591292 |
Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.
Condition | Intervention | Phase |
---|---|---|
Solid Tumors |
Drug: indibulin |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors |
Estimated Enrollment: | 20 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single Arm: Experimental |
Drug: indibulin
Dose escalation of indibulin given twice daily for up to 6 months
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted < 2 weeks prior to Baseline:
Exclusion Criteria
Contact: Patrice Nikolis | 617-259-1976 | pnikolis@ziopharm.com |
Contact: Jan Stevens | 617-259-1983 | jstevens@ziopharm.com |
United States, California | |
Recruiting | |
Santa Monica, California, United States |
Responsible Party: | ZIOPHARM Oncology, Inc ( Jon Lewis, Chief Medical Officer ) |
Study ID Numbers: | IBL1002 |
Study First Received: | December 26, 2007 |
Last Updated: | August 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00591292 |
Health Authority: | United States: Food and Drug Administration |
cancer tumor solid tumor advanced tumor |